Government News

  • “The General Budget 2019-20 is a reflection of the pragmatism and visionary governance of our Prime Minister Shri Narendra Modiji. It is development-oriented and people-centric.A landmark budget was presented today by the Finance Minister Smt. Nirmala Sitharaman with the agenda of “putting the nation first”. This was stated by Dr. Harsh Vardhan, Union Minister for Health and Family Welfare while welcoming the Union Budget for the year 2019-20. Thanking the Prime Minister Shri Narendra Modiji and the Finance Minister, Dr Harsh Vardhan further said that this is an inclusive budget which is pro-poor, pro-farmer, pro-downtrodden and for the development of all the sectors and the country at large.

  • 11 June 2019
    ePharmacy is looking towards health profession as business : AIOCD

    The E-Pharmacy is an off-shoot of modern technology. The benefits of internet pharmacies propagated are convenience; allow the door delivery of drugs at low cost, but the picture presented is misleading and hiding the facts, says All India Organisation of Chemists and Druggists (AIOCD) as a objection towards ePharmacy working in India.

  • The Competition Commission of India (‘Commission’) has found Madhya Pradesh Chemists and Druggist Association (‘MPCDA’), Indore Chemists Association (‘ICA’), Himalaya Drug Company (‘HDC’) and Intas Pharmaceuticals Limited (‘IPL’) along with some of their office bearers/officials to be in contravention of the provisions of the Competition Act, 2002 (‘Act’).

  • 30 May 2019
    IMA strongly opposes move by PCI to use Dr prefix for Pharm.D

    Pharmacy Council of India has reportedly directed universities to use the prefix 'Doctor (Dr)' while awarding degrees to Pharm.D graduates. Indian Medical Association strongly opposes any move from those who are trained in other streams of Health sector to venture into medical practice.

  • Indian Pharmacists Association (IPA) strictly opposes use of the post name Dispensing Attendant instead of Pharmacist for recent recruitment advertisement by AIIMS Rishikesh. As per IPA, the advertisement No. 2019/153 by AIIMS Rishikesh is violating Pharmacy Act and Drugs and Cosmetic rules.

  • Limited access to essential medicines for treating chronic diseases is a major challenge in low and middle-income countries. Although India is the largest manufacturer of generic medicines, there is a paucity of information on availability, price and affordability of essential anti-cancer medicines used for treating childhood cancers.

  • EMA is advising healthcare professionals and patients not to exceed the recommended dose of Xeljanz (tofacitinib) when treating rheumatoid arthritis. The advice follows early results from an ongoing study (study A3921133) in patients with rheumatoid arthritis which showed an increased risk of blood clots in the lungs and death when the normal dose of 5 mg twice daily was doubled.

Subscribe to Government News